To elucidate the role of specific proinflammatory cytokines in regulating airway responsiveness, we examined the effects and mechanisms of action of IL-1 ␤ , TNF-␣ , and IL-2 on the ␤ -adrenoceptor-and postreceptor-coupled transmembrane signaling mechanisms regulating relaxation in isolated rabbit tracheal smooth muscle (TSM) segments. During half-maximal isometric contraction of the tissues with acetylcholine, relaxation responses to isoproterenol, PGE 2 , and forskolin were separately compared in control (untreated) TSM and tissues incubated for 18 h with IL-1 ␤ (10 ng/ml), TNF-␣ (100 ng/ml), or IL-2 (200 ng/ml). Relative to controls, IL-1 ␤ -and TNF-␣ -treated TSM, but not IL-2-treated tissues, depicted significant attenuation of their maximal relaxation and sensitivity (i.e., Ϫ log dose producing 50% maximal relaxation) to isoproterenol ( P Ͻ 0.001) and PGE 2 ( P Ͻ 0.05); whereas the relaxation responses to direct stimulation of adenylate cyclase with forskolin were similar in the control and cytokine-treated tissues. Further, the attenuated relaxation to isoproterenol and PGE 2 was ablated in the IL-1 ␤ -treated TSM that were pretreated with either the muscarinic M 2 -receptor antagonist, methoctramine (10 
Introduction
There is increasing evidence that a variety of cytokines, including the pleiotropic inflammatory mediators, IL-1 ␤ and TNF-␣ , play important roles in orchestrating and perpetuating the airway inflammatory response in asthma (1) (2) (3) (4) (5) (6) (7) . In this regard, a number of studies have demonstrated increased concentrations of various cytokines in the bronchoalveolar lavage fluid isolated from allergic asthmatic individuals (8) (9) (10) . While the precise role of each cytokine remains to be established, collectively, these agents have been found to exert a diversity of actions including induction of specific IgE production by mononuclear cells (11) (12) , antigen presentation by macrophages (13) , activation of airway structural cells (5, (14) (15) (16) , altered expression of adhesion molecules (17, 18) , induced secretion of various growth factors (19, 20) , recruitment of inflammatory cells from the circulation (21) (22) (23) (24) , and other proinflammatory events.
Apart from their above actions, there is also emerging evidence that specific cytokines, most notably IL-1 ␤ and TNF-␣ , also play an important role in regulating the changes in airway smooth muscle contractility which characterize the asthmatic phenotype. In this connection, exogenous administration of TNF-␣ to animals in vivo has been shown to induce bronchial constrictor hyperresponsiveness (6, 25) , and treatment of isolated guinea pig airways with IL-1 ␤ or TNF-␣ has been found to reduce isoproterenol-mediated relaxation in vitro (26) . Moreover, treatment of antigen-sensitized animals with an IL-1 receptor antagonist has been shown to inhibit both their in vivo bronchial hyperreactivity to histamine (2) or substance P (27) , as well as the accompanying pulmonary infiltration with leukocytes, including eosinophils and neutrophils (2, 27, 28) . Collectively, these recent observations support the compelling concept that certain proinflammatory cytokines may be directly involved in mediating changes in airway contractility. The potential mechanisms underlying such cytokine-induced pertubations in airway smooth muscle responsiveness, however, remain to be identified.
In addressing the above issue, this study examined the effects of specific proinflammatory cytokines on the relative contributions of ␤ -adrenoceptor-and postreceptor-coupled transmembrane signaling mechanisms regulating airway relaxation. The results provide new evidence demonstrating that: ( a ) IL-1 ␤ and, to a lesser extent, TNF-␣ , induce attenuated ␤ -adrenoceptor-mediated airway relaxation; ( b ) the latter is associated with enhanced muscarinic M 2 -receptor-coupled activation of the guanine nucleotide binding protein, G i ; and ( c ) the enhanced G i -coupled function is related to induced increased expression of the G i ␣ 2 and G i ␣ 3 subunits in membranes from cytokine-treated airway smooth muscle.
Methods
Animals. 28 adult New Zealand White rabbits were used in this study which was approved by the Biosafety and Animal Research Commit-tee of the Joseph Stokes Research Institute at Children's Hospital of Philadelphia. The animals had no signs of respiratory disease for several weeks before the study.
Cytokine pretreatment and preparation of tissues. After anesthesia with xylazine (10 mg/kg) and ketamine (50 mg/kg), the animals were killed with systemic air embolism. The tracheas were removed via open thoracotomy, cleared of loose connective tissue, divided into eight ring segments of 6-8 mm in length, and incubated over 18 h at room temperature in Dulbecco's modified Eagle's medium containing either: IL-1 ␤ (10 ng/ml); TNF-␣ (100 ng/ml); IL-1 ␤ (10 ng/ml) and TNF-␣ (100 ng/ml) together; IL-2 (200 ng/ml); or medium alone containing no cytokine. The medium was aerated with a continuous supplemental O 2 mixture (95% O 2 /5% CO 2 ) during the incubation phase.
Pharmacodynamic studies. After incubation, each airway segment was suspended longitudinally between stainless steel triangular supports in siliconized 20-ml organ baths (Harvard Apparatus, Inc., South Natick, MA). The lower support was secured to the base of the organ bath, and the upper support was attached via a gold chain to a force transducer (FT.03C; Grass Instrument Co., Quincy, MA) from which isometric tension was continuously displayed on a multichannel recorder. Care was taken not to injure the epithelia and to place the membranous portion of the trachea between the supports to maximize the recorded tension generated by the contracting trachealis muscle.
The tissues were bathed in modified Krebs-Ringer solution containing (mM) 125 NaCl, 14 NaHCO 3 , 4 KCl, 2.25 CaCl 2 и 2H 2 O, 1.46 MgSO 4 и 7H 2 O, 1.2 NaH 2 PO 4 и H 2 O, and 11 glucose. The baths were aerated with 5% CO 2 in oxygen, a pH of 7.35-7.40 was maintained, and the temperature was held at 37 Њ C. Passive resting tension of each tracheal smooth muscle (TSM) 1 segment was set at 2.0 g after each tissue had been passively stretched to a tension of 8 g to optimize the resting length of each segment (29) . The tissues were allowed to equilibrate in the bath for 45 min, at which time each tissue was primed with a 1-min exposure to 10 Ϫ 4 M acetylcholine (ACh). Cholinergic contractility was initially assessed in the TSM by cumulative administration of ACh in final bath concentrations ranging from 10 Ϫ 9 to 10 Ϫ 3 M. After thorough rinsing, each tissue segment was then half-maximally contracted with individual concentrations of ACh in the absence and presence of the muscarinic M 2 -receptor antagonist methoctramine (10 Ϫ 6 M). Thereafter, in separate studies, the tissues were treated with cumulative administration of isoproterenol (10 Ϫ 9 to 10 Ϫ 4 M), PGE 2 (10 Ϫ 9 to 10 4 M), or forskolin (10 Ϫ 9 to 10 Ϫ 4 M). In other studies, relaxation dose-response curves to isoproterenol (10 Ϫ 9 to 10 Ϫ 4 M) and forskolin (10 Ϫ 9 to 10 Ϫ 4 M) were conducted in paired IL-1 ␤ -treated and control tissues in the presence and absence of ADP ribosylation of G i by pretreatment of the tissues for 18 h with pertussis toxin (PT; 100 ng/ml) (30). Additionally, in separate experiments, relaxation responses to isoproterenol were assessed in TSM segments in the presence and absence of the IL-1 receptor antagonist (150 ng/ml). The relaxant responses to isoproterenol, PGE 2 , and forskolin were analyzed in terms of percent maximal relaxation (R max ) from the active cholinergic contraction, and sensitivity to the relaxing agent was determined as the negative logarithm of the dose of the relaxing agent producing 50% of R max (pD 50 ) (i.e., geometric mean ED 50 value).
Determination of G i protein expression. Expression of the inhibitory G i protein and its ␣ -subunits was assayed by Western blot analysis of membrane protein samples isolated from both IL-1 ␤ -treated ( n ϭ 6) and control ( n ϭ 6) rabbit TSM in two separate experiments. The membrane protein samples were prepared as follows. Trachealis muscle was minced and homogenized using a Dounce tissue grinder (Wheaton Industries, Millville, NJ) in 40 vol of 50 mM Tris-HC1, 150 mM NaCl, 1 mM EDTA (pH 7.4) containing 1 mM PMSF, 5 g/ml aprotinin, and 5 g/ml leupeptin. Nuclei and large particulates were removed by centrifugation at 100 g for 5 min. The supernatant was then centrifuged at 100,000 g for 1 h to pellet the membrane fractions. The membrane pellet was resuspended in the same Tris-EDTA buffer, and the protein concentration was measured using the Lowry assay. Equivalent amounts (30-50 g) of membrane protein were fractionated in 11% SDS-polyacrylamide gels followed by transfer to nitrocellulose membranes. The membranes were then blotted overnight at room temperature in 25 mM Tris-HCl (pH 7.5), 150 mM NaCl, and 0.05% Tergitol NP-40 containing 5% nonfat milk. The rabbit polyclonal anti-G i -common, G i ␣ 1 , G i ␣ 2 , and G i ␣ 3 antibodies were diluted at 1:1,000, 1:500, 1:500, and 1:500, respectively, and were incubated for 2 h at room temperature. The G i -common antiserum recognizes G i ␣ 1 , G i ␣ 2 , and G i ␣ 3 equivalently (31). The primary G i antibodies were the generous gift of Dr. David Manning (University of Pennsylvania). All primary and secondary antibody incubations and washes were done in 25 mM Tris-HCl (pH 7.5), 150 mM NaCl, and 0.05% NP-40 containing 0.50% nonfat milk. The G i proteins were detected using enhanced chemiluminescence (Amersham, Arlington Heights, IL) after a 1-h incubation with a 1:3,000 dilution of an antirabbit horseradish peroxidase-linked secondary antibody and subsequent exposure to autoradiography film. Expression levels of common and specific G i ␣-subunit proteins were quantitated using laser densitometry (Bio Rad Laboratories, Hercules, CA).
Determination of cAMP accumulation. To determine whether ␤-adrenoceptor-mediated cAMP accumulation was altered by IL-1␤, isoproterenol-stimulated time-and dose-dependent cAMP generation was assayed in IL-1␤-treated (n ϭ 6) and control (n ϭ 6) tissues. For the time-response studies, TSM were isolated and prepared as described above. The airway epithelium was removed by scraping and, after resecting the cartilage, the trachealis muscle was divided into separate segments and each segment was exposed to isoproterenol (10 Ϫ5 M) for 0, 0.5, 1, 2, 3, or 5 min. For the dose-response studies, the cAMP level was determined at 1 min after exposure of IL-1␤-treated and control TSM to varying concentrations of isoproterenol (10 Ϫ7 to 10 Ϫ4 M). In all experiments, the tissues were treated with the phosphodiesterase inhibitor, 3-isobutyl-1-methylxanthine (10 Ϫ5 M), for 30 min before isoproterenol administration. In these studies, after homogenization of the tissues, cAMP generation was determined with the use of a commercially available radioimmunoassay, with [ 3 H]cAMP as tracer (Amersham). The tissues' protein concentration was assayed using the Lowry method, and the cAMP measurements were expressed in units of picomoles per milligram of tissue membrane protein.
Radioligand binding studies. To identify whether muscarinic receptor maximal binding capacity (B max ) and dissociation constant (K d ) were altered by IL-1␤, membrane preparations from IL-1␤-treated (n ϭ 4) and control (n ϭ 4) trachealis tissues were treated with the hydrophilic selective muscarinic radioligand, [N-methyl- Ϫ4 M and 10 Ϫ6 M solutions, respectively. Addition of these dilutents to the organ bath at the appropriate concentrations had no effect on the resting nor half-maximal cholinergic tone of the TSM.
Results
Cytokine effects on cholinergic contractility. To assess the actions of specific proinflammatory cytokines in regulating the TSM constrictor response to cholinergic stimulation, contractile dose-response relationships to ACh were separately compared between IL-1␤-, TNF-␣-, or IL-2-treated tissues and their respective paired control (untreated) TSM segments. In tissues incubated for 18 h with a maximally effective concentration of IL-1␤ (10 ng/ml), maximal constrictor responsiveness to ACh was significantly increased, wherein the meanϮ SE maximal isometric force (T max ) amounted to 140.0Ϯ6.8 grams/gram of tissue weight, compared with the value of 116.6Ϯ5.7 grams/gram of tissue weight obtained in corresponding controls (P Ͻ 0.01) (Fig. 1 A) . However, constrictor sensitivity to ACh was similar in the IL-1␤-treated and control tissues, wherein the pD 50 (i.e., Ϫlog ED 50 ) values amounted to 5.50Ϯ0.04 and 5.52Ϯ0.05 Ϫlog M, respectively. In contrast to IL-1␤, neither the T max nor pD 50 values for ACh were significantly different between the TNF-␣-or IL-2-treated tissues and their respective controls. However, when maximally effective concentrations of IL-1␤ (10 ng/ml) and TNF-␣ (100 ng/ml) were administered together, the mean T max and pD 50 values to ACh were significantly synergistically enhanced and amounted to 152.8Ϯ10.2 grams/gram of tissue weight and 5.78Ϯ0.05 Ϫlog M vs. 127.8Ϯ6.9 grams/gram of tissue weight (P Ͻ 0.001) and 5.27Ϯ0.16 Ϫlog M (P Ͻ 0.01) in the corresponding controls, respectively.
Cytokine effects on airway relaxation. In separate studies, during comparable levels of initial sustained ACh-induced contractions in IL-1␤-treated and control airway segments, averaging 37.9Ϯ0.9 and 39.7Ϯ1.4% of T max , respectively, administration of the ␤-adrenergic agonist, isoproterenol, PGE 2 , or the direct adenylate cyclase activator, forskolin, elicited cumulative dose-dependent relaxation of the precontracted TSM segments. Relative to their respective controls, the R max and pD 50 to isoproterenol (Fig. 2 A) and PGE 2 (Fig. 2 B) were significantly attenuated in the IL-1␤-treated tissues. Accordingly, the mean R max values for isoproterenol amounted to 34.6Ϯ2.6 and 55.0Ϯ4.0% in the IL-1␤-treated and control TSM, respectively (P Ͻ 0.001), with corresponding pD 50 values of 6.30Ϯ0.05 and 6.53Ϯ0.05 Ϫlog M, respectively (P Ͻ 0.01). Similarly, the mean R max values of PGE 2 averaged 52.6Ϯ4.5 and 68.0Ϯ6.6% in the IL-1␤-treated and control tissues, respectively (P Ͻ 0.05), with corresponding pD 50 values of 5.70Ϯ0.68 and 6.03Ϯ0.09 Ϫlog M, respectively (P Ͻ 0.01). In contrast, there were no differences in the relaxation responses to forskolin between the tissue groups, wherein the mean R max values averaged 92.0Ϯ2.1 and 95.0Ϯ2.8% in IL-1␤-treated and control TSM segments, respectively (P ϭ 0.85), and the corresponding pD 50 values were similar at 6.29Ϯ0.11 and 6.36Ϯ0.07 Ϫlog M, respectively (P ϭ 0.64). Thus, whereas reversal of ACh-induced airway constriction with isoproterenol and PGE 2, both of which are associated with receptor/G protein-coupled activation of adenylate cyclase, was attenuated in IL-1␤-treated tissues, the relaxant effectiveness of forskolin, a diterpene that directly activates the catalytic unit of adenylate cyclase, was unaltered in the tissues treated with IL-1␤. Of note, the above IL-1␤-induced changes in ␤-adrenoceptor re- sponsiveness were prevented by coincubation of the airway segments with the human recombinant IL-1 receptor antagonist (150 ng/ml), while the latter alone had no effect on either the contractile responses to ACh or relaxation responsiveness to isoproterenol in control tissues (data not shown).
Qualitatively similar changes in ␤-adrenoceptor responsiveness were observed in TSM treated with TNF-␣ (100 ng/ ml), although their degree of attenuation in relaxation responsiveness to isoproterenol was less pronounced, providing mean R max values of 46.5Ϯ2.9 vs. 54.4Ϯ3.2% in the corresponding controls (P Ͻ 0.05). Similarly, there were no differences in the relaxant responses to forskolin between TNF-␣-treated and control tissue groups. However, when maximally effective concentrations of IL-1␤ (10 ng/ml) and TNF-␣ (100 ng/ml) were administered together, there occurred a synergistic attenuation of the relaxant responsiveness to isoproterenol (Fig. 3) , relative to the effect produced by IL-1␤ alone (dashed function). In the presence of IL-1␤ and TNF-␣, both the R max and pD 50 were significantly reduced at 23.5Ϯ3.2% (vs. 63.0Ϯ5.2% in controls; P Ͻ 0.001) and 6.01Ϯ0.05 Ϫlog M (vs. 6.36Ϯ0.11 Ϫlog M in controls; P Ͻ 0.01). In contrast to IL-1␤ and TNF-␣, relaxation responsiveness to isoproterenol or PGE 2 was unaffected in IL-2-treated tissues.
In light of the above observations, we next examined whether the IL-1␤-induced changes in agonist-mediated reversal of ACh-induced airway constriction were related to altered muscarinic M 2 -receptor-coupled modulation of agonistinduced airway relaxation. Accordingly, relaxation-response curves to isoproterenol, PGE 2 , and forskolin were compared in paired IL-1␤-treated and control tissues wherein one of each tissue pair was pretreated for 45 min with the muscarinic M 2 -receptor antagonist, methoctramine (10 Ϫ6 M). The latter significantly potentiated the airway relaxation responses to isoproterenol in IL-1␤-treated tissues half-maximally precontracted with ACh (Fig. 4 B) . In contrast, methoctramine had relatively little effect on the relaxant responsiveness to the ␤-adrenergic agonist in control tissues (Fig. 4 A) . Moreover, it should be noted that the magnitude of enhancement in ␤-adrenoceptor responsiveness in the IL-1␤-treated tissues that were preexposed to methoctramine yielded R max and pD 50 values for isoproterenol (i.e., 52.3Ϯ4.1% and 6.63Ϯ0.08 Ϫlog M, respectively) that were not significantly different from those obtained in corresponding control TSM segments (P ϭ 0.65). Similarly, in the presence of methoctramine, PGE 2 -induced airway relaxation was also selectively enhanced in the IL-1␤-treated tissues, yielding R max and pD 50 values for PGE 2 which were similar to those obtained in corresponding methoctramine-treated control airway segments. In contrast, relaxant responsiveness to forskolin was unaltered by methoctramine in either the IL-1␤-treated or control tissues (data not shown).
Given the above findings with methoctramine, and that muscarinic M 2 -receptor activation is known to be associated with G i protein-coupled inhibition of adenylate cyclase (30, [32] [33] [34] , in parallel experiments we examined whether ADP-ribosylation of G i with PT also modulates the attenuated airway relaxant responsiveness to isoproterenol in IL-1␤-treated tissues. Accordingly, relaxation response curves to isoproterenol, PGE 2 , and forskolin were compared in groups of paired control and IL-1␤-treated tissues wherein one of each pair was pretreated for 18 h with PT (100 ng/m1). The latter significantly enhanced the relaxation responses to isoproterenol in IL-1-treated TSM (Fig. 5 B) , but had no effect on the responses in corresponding control tissues (Fig. 5 A) . Comparable results were obtained with PGE 2 -induced airway relaxation and, of note, PT had no effect on the R max and pD 50 values to forskolin (data not shown). Moreover, the R max and pD 50 values to isoproterenol obtained after PT exposure of IL-1␤-treated tissues (i.e., 57.1Ϯ0.2% and 6.40Ϯ0.45 Ϫlog M, respectively) were similar to those obtained in control TSM (P ϭ 0.38). Thus, these observations are consistent with the presence of enhanced muscarinic M 2 -receptor/G i protein-coupled inhibition of isoproterenol-and PGE 2 -induced relaxation in IL-1␤-treated TSM.
cAMP accumulation. To determine whether the enhanced muscarinic M 2 -receptor/G i protein-coupled inhibition of isoproterenol-induced airway relaxation was associated with changes in receptor-mediated accumulation of cAMP in the cytokine-treated tissues, the dose-dependent effects of isoproterenol on cAMP accumulation were compared in IL-1␤-treated and control TSM segments. The mean (ϮSE) resting (baseline) levels of cAMP were similar in unstimulated control and IL-1␤-treated TSM, averaging 7.5Ϯ1.5 and 7.7Ϯ1.2 pmol/mg protein, respectively. In contrast, the peak increases in cAMP accumulation at 1 min after each administered dose of isoproterenol were significantly reduced in the IL-1␤-treated tissues, as exemplified by a representative experiment comparing isoproterenol-induced cAMP accumulation in paired control and IL-1␤-treated TSM (Fig. 6) . Comparable results were ob- tained in the other experiments (n ϭ 4), wherein the collective meanϮSE maximal increases in cAMP in response to 10 Ϫ5 M isoproterenol amounted to 25.4Ϯ2.5 and 17.6Ϯ2.3 pmol/mg protein in the control and IL-1␤-treated TSM, respectively (P Ͻ 0.01).
G i protein expression. In view of the above pharmacodynamic evidence of enhanced muscarinic M 2 -receptor/G i protein-coupled attenuation of airway responsiveness to isoproterenol in IL-1␤-treated TSM, we next examined whether the expression of G i and its isoforms is modulated in plasma membranes isolated from IL-1␤-treated tissues. Relative to controls, Western immunoblot analyses of G i -common and specific G i ␣-subunit expression in membrane homogenates from IL-1␤-treated TSM demonstrated increased levels of G i -common, G i ␣ 2 , and G i ␣ 3 , the latter qualified by laser densitometry at 251 (P Ͻ 0.01), 393 (P Ͻ 0.001), and 303% of control (P Ͻ 0.005), respectively (Fig. 7) . In contrast, G i ␣ 1 expression was not significantly different between control and IL-1␤-treated TSM membrane fractions (data not shown).
Muscarinic radioligand binding. Muscarinic-cholinergic receptor binding using the radioligand [N-methyl- (Fig. 8) .
Discussion
In recent years, substantial evidence has been accumulated in support of the concept that cytokines are key regulators of the cascade of cellular events associated with airway inflammation in atopic asthma (2, 27, (35) (36) (37) (38) . In this regard, some studies have demonstrated elevated levels of various cytokines in the bronchoalveolar lavage fluid from asthmatic patients (8-10). Moreover, recent animal studies have shown that, apart from their potential role in regulating airway inflammation in the allergic state, certain cytokines (notably IL-1␤ and TNF-␣) may also contribute to the associated heightened airway constrictor responsiveness (2, 6, 25, 27) . Finally, administration of specific cytokines has been shown to induce impairment of ␤-adrenoceptor-mediated airway relaxation in the isolated guinea pig trachea (26) . Thus, taken together, these studies implicate a role for proinflammatory cytokines in mediating certain changes in airway contractility which characterize the asthmatic phenotype. In view of the latter, and to elucidate the mechanism(s) underlying any cytokine-induced modulation of airway responsiveness, the present study examined the actions of specific cytokines on the relative contributions of ␤-adrenoceptor-and postreceptor-coupled transmembrane signaling mechanisms regulating airway smooth muscle relaxation. Our results demonstrated that: (a) IL-1␤ alone, and to a lesser extent, TNF-␣, produces attenuation of ␤-adrenoceptor-mediated airway relaxation; (b) the latter effect is attributed to cytokine-induced enhanced muscarinic M 2 -receptor/G i protein coupling; and (c) when given together, IL-1␤ and TNF-␣ exert a synergistic attenuating effect on ␤-adrenoceptor-mediated airway relaxation.
The observed reduced relaxation responses of IL-1␤-treated airways to ␤-adrenoceptor stimulation were not specific to activation of the ␤-adrenergic receptor, since attenuated relaxation responses to PGE 2 were also observed in these cytokinetreated tissues (Fig. 2) . These observations, together with the finding that the airway relaxant responses to direct activation of adenylate cyclase with forskolin was unaltered in IL-1␤-treated tissues, suggest that the cytokine action was associated with attenuation of a receptor-coupled signaling mechanism upstream to adenylate cyclase activation. Additionally, our observations also demonstrated reversal of the attenuated ␤-adrenoceptor-and PGE 2 -mediated airway relaxation by muscarinic M 2 -receptor blockade with methoctramine ( Fig. 4) and by ADP-ribosylation of G i protein with PT ( Fig. 5) , suggesting that the cytokine-induced impairment of airway relaxation was likely attributed to enhanced M 2 -receptor/G i protein-coupled inhibition of adenylate cyclase. Indeed, in related experiments, we found reduced isoproterenol-stimulated cAMP accumulation in IL-1␤-treated versus control TSM (Fig. 6) . Moreover, in this context, it should be noted that since the relaxation responses to isoproterenol and PGE 2 obtained in IL-1␤-treated tissues preexposed to the M 2 -receptor antagonist or PT were similar to those generated in control airways (Figs. 4 and 5), our observations further suggest that the attenuated relaxation responses in the IL-1␤-treated tissues occurred largely independent of any concomitant significant changes in intrinsic ␤-adrenoceptor or PGE 2 receptor expression or G s protein coupling.
Taken together, our present findings largely concur with the known inhibitory action of muscarinic M 2 -receptor activation on adenylate cyclase activity in other cell systems (39) (40) (41) (42) , and agree with the established evidence that the functional responses to both ␤-adrenoceptor and PGE 2 receptor stimulation are downregulated by G i protein activation (39) (40) (41) (42) (43) (44) . Moreover, in this regard, insofar as the TSM relaxation responses to isoproterenol were virtually unaffected by methoctramine or PT in control tissues (Figs. 3 and 4) , our findings further suggest that the contribution of the above M 2 -receptor/G i proteincoupled action is relatively insignificant under control conditions. Thus, collectively, the observations support the concept that IL-1␤ induces muscarinic M 2 -receptor/G i protein-coupled inhibition of ␤-adrenoceptor-and PGE 2 -mediated airway relaxation associated with attenuated cAMP accumulation.
In further examining the above mechanism, we found that G i protein expression was increased in membranes isolated from IL-1␤-treated TSM, a finding associated with specific enhanced expression of the G i ␣ 2 and G i ␣ 3 subunits (Fig. 7) . However, expression of the G i ␣ 1 subunit was found to be similar in IL-1␤-treated and control TSM membranes. Of interest, these findings agree with our recent observations in atopic passively sensitized rabbit TSM wherein attenuated ␤-adrenoceptormediated airway relaxation was also found to be associated with increased G i ␣ 3 subunit expression (30). Moreover, in this context, it is relevant to note that elevated levels of G i ␣ 2 have been detected in lung membranes from antigen-challenged guinea pigs (26) , and that IL-1␤ administration was found to induce increased mRNA expression of G i ␣ 2 in guinea pig TSM (45) and in cultured human endothelial cells (46) . Thus, given our present observations and those of the above earlier studies, the consideration is raised that while changes in ␤-adrenergic function in cytokine-treated or atopic sensitized airways may be related to altered G i protein expression, the latter effect may be species specific with respect to the G i ␣ subtypes involved, wherein G i ␣ 2 and G i ␣ 3 are both altered in rabbits while a potential more selective effect on G i ␣ 2 expression alone is seen in guinea pig and human tissues.
Although the mechanism accounting for the cytokineinduced increased G i protein expression (including altered transcriptional and/or posttranscriptional regulation) remains to be determined, in contrast to changes in G i protein expression, our extended findings demonstrated that neither muscarinic-cholinergic receptor density nor affinity was altered in IL-1␤-treated TSM membranes (Fig. 7) . Taken together, these findings along with earlier observations demonstrating both a significant muscarinic receptor reserve (i.e., spare receptors) in TSM (47) and that Ͼ 70% of rabbit airway muscarinic receptors are of the M 2 -receptor subtype (48) allow for the compelling speculation that the attenuated ␤-adrenoceptor-mediated relaxation in IL-1␤-treated TSM reflects enhanced functional coupling of the increased G i protein to spare muscarinic receptors. This possibility remains to be systematically addressed in extended studies.
In conclusion, this study examined the role and mechanisms of action of specific proinflammatory cytokines in regulating rabbit airway smooth muscle relaxation. The results demonstrated that: (a) during cholinergic stimulation, IL-1␤ alone, and to a lesser extent, TNF-␣ (but not IL-2), produces attenuated relaxation of TSM to isoproterenol and PGE 2 , but not to direct activation of adenylate cyclase with forskolin; (b) the latter combined effects of IL-1␤ and TNF-␣ are synergistic; (c) the attenuated relaxation to isoproterenol and PGE 2 is ablated in cytokine-treated tissues preexposed to either a muscarinic M 2 -receptor antagonist or PT; (d) the impaired ␤-adrenoceptor-mediated relaxation is associated with reduced isoproterenolstimulated cAMP accumulation in IL-1␤-treated TSM; (e) the impaired relaxation to isoproterenol is not accompanied by changes in muscarinic-cholinergic receptor binding in IL-1␤-treated tissues; and (f) the attenuated relaxation to ␤-adrenoceptor stimulation is associated with IL-1␤-induced enhanced G i protein expression in TSM membrane, attributed to increased expression of both the G i ␣ 2 and G i ␣ 3 subunits. Collectively, these observations provide new evidence implicating enhanced muscarinic M 2 -receptor/G i protein coupling in mediating cytokine-induced impairment of airway relaxation to ␤-adrenoceptor stimulation, a phenomenon which may account for attenuated airway relaxation in the atopic/asthmatic state.
